In Canada, two individuals have tragically died after donating plasma at a network of clinics run by the Spanish company Grifols. This incident is particularly concerning as the clinics have been under federal scrutiny for not maintaining accurate donor records, failing to properly screen donors, and neglecting the proper maintenance of their equipment. Experts acknowledge that while such deaths are exceedingly rare, this situation brings to light significant concerns regarding the integrity of private plasma donation operations in the country.

Health Canada, the agency responsible for regulating plasma clinics, confirmed that it had received reports about 'fatal adverse reactions' linked to these donations which occurred in late 2025 and early 2026. The regulatory body is currently investigating the circumstances surrounding these deaths, as both donors reportedly experienced severe distress during the donation process. Critics argue that Canada’s growing reliance on private entities for blood products may jeopardize the quality and safety of plasma, viewing this move as indicative of a gradual decline in the country's previously robust public health system.

Grifols has issued a statement asserting that they do not believe there is any correlation between the donors' deaths and their plasma donation experiences. Nonetheless, the incident raises pressing questions about the oversight of private plasma clinics in Canada and the potential implications for public health policy related to blood products, especially considering the ongoing debates about privatization and health care standards in the country.